Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Recommendation of “Hold” from Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been given an average rating of “Hold” by the ten ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $9.33.

Several research firms have weighed in on FULC. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th.

Fulcrum Therapeutics Stock Down 3.7 %

NASDAQ FULC opened at $3.69 on Monday. Fulcrum Therapeutics has a 52 week low of $2.86 and a 52 week high of $13.70. The business’s fifty day simple moving average is $4.23 and its 200-day simple moving average is $5.08. The firm has a market cap of $199.04 million, a PE ratio of -11.90 and a beta of 2.03.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in FULC. Dimensional Fund Advisors LP boosted its holdings in Fulcrum Therapeutics by 13.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company’s stock valued at $9,182,000 after purchasing an additional 176,114 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Fulcrum Therapeutics in the second quarter valued at approximately $82,000. The Manufacturers Life Insurance Company acquired a new position in Fulcrum Therapeutics during the second quarter worth $152,000. Algert Global LLC lifted its holdings in Fulcrum Therapeutics by 202.1% in the second quarter. Algert Global LLC now owns 41,303 shares of the company’s stock valued at $256,000 after acquiring an additional 27,633 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in Fulcrum Therapeutics by 26.5% in the third quarter. SG Americas Securities LLC now owns 33,019 shares of the company’s stock valued at $118,000 after acquiring an additional 6,926 shares during the period. 89.83% of the stock is currently owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.